Retraction to "Thyroid Cancer Cell Resistance to Gefitinib Depends on the Constitutive Oncogenic Activation of the ERK Pathway". . J Clin Endocrinol Metab 2023 Feb 28:dgad056. doi: 10.1210.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Retraction to "Thyroid Cancer Cell Resistance to Gefitinib Depends on the Constitutive Oncogenic Activation of the ERK Pathway". J Clin Endocrinol Metab 2023 Feb 28:dgad056. doi: 10.1210.
PMID: 36848947